Symatese announces its partnership with Evolus in the USA regarding its new range of HA dermal fillers

Symatese has just concluded an agreement for its range of dermal fillers, based on its First-Generation Cold Technology HA, with Evolus, one of the major players in the American market. According to Jean-Paul Gérardin, CEO of SYMATESE, “this new partnership represents a tremendous growth lever for the organization which will launch its new range of products in various territories based on solid clinical data”. For more details access the press release & presentation